



Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/650326
				Filing Date	August 28, 2003
				First Named Inventor	Keith A. Hruska
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	JJJ-P01-599

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CB	AA	US-5,011,691	04-30-1992	Oppermann et al.	
CB	AB	US-5,266,683	11-30-1993	Oppermann et al.	
CB	AC	US-4,968,590	11-06-1990	Kubera Sampath et al.	
CB	AD	US-5,723,441	03-03-1998	Higley et al.	
CB	AE	US-5,849,686	12-15-1998	Kubera Sampath et al.	
CB	AF	US-5,879,908	03-09-1999	Laping et al.	
CB	AG	US-5,733,441	03-03-1998	Higley et al.	
CB	AH	US-6,120,760	09-19-2000	Hotten et al.	
CB	AI	US-6,498,142	12-24-2002	Sampath et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
CB	BA	WO 92/15223	10-17-1991	Amgen Inc.	
CB	BB	WO 93/04692	03-18-1993	Creative Biomolecules, Inc.	
CB	BC	WO 94/03200	02-17-1994	Creative Biomolecules, Inc.	
CB	BD	WO 98/50060	11-12-1998	Creative Biomolecules, Inc.	
CB	BE	WO 97/41880	11-13-1997	Creative Biomolecules, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
CB	CA	VUKICEVIC et al., "Developing Human Lung and Kidney are Major Sites for Synthesis of Bone Morphogenetic Protein-3 (Osteogenin)", (1994), J. Histochem. Cytochem. 42:869-875			
CB	CB	JONES, et al., "Involvement of Bone Morphogenetic Protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse", (1991) Development 111: 531-542			
CB	CC	VUKICEVIC, et al., "Localization of Osteogenic Protein-1 (Bone Morphogenetic Protein-7) During Human Embryonic Development: High Affinity Binding to Basement Membranes", (1994) Biochem. Biophys. Res. Commun. 198: 693-700			
CB	CD	OZKAYNAK, et al. (1992) "Osteogenic Protein-2 A New Member of the Transforming Growth Factor-β Superfamily Expressed Early in Embryogenesis", J. Biol. Chem. 267: 25220-25227			
CB	CE	OZKAYNAK, et al., "Murine Osteogenic Protein (OP-1): High Levels of mRNA in Kidney", (1991) Biochem. Biophys. Res. Commun. 179: 116-123.			
Examiner Signature	<i>Christina Borgest</i>			Date Considered	9/5/06

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	3	Attorney Docket Number	JJJ-P01-599
-------	---	----	---	------------------------	-------------

		Complete if Known			
		Application Number	10/650326		
		Filing Date	August 28, 2003		
		First Named Inventor	Keith A. Hruska		
		Art Unit	1614		
		Examiner Name	Not Yet Assigned		
CB	CF	HRUSKA, K.A., et al.. 2000. "Osteogenic protein-1 (OP-1) prevents renal fibrogenesis associated with ureteral obstruction", Am J Phys (Renal) 279:F130-F143			
CB	CG	LUO,G., et al., 1995. "BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning" Genes Dev. 9:2808-2820.			
CB	CH	DUDLEY,A.T., et al., 1995. "A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye". Genes Dev 9:2795-2807			
CB	CI	VUKICEVIC,S. et al., 1996. "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)" Proc. Natl. Acad. Sci. U.S.A. 93:9021-9026			
CB	CJ	KISPERT A., et al., 1998 "Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney", Development 125:4225-4234.			
CB	CK	SIMON,M., et al., 1999. "Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney", Amer.J.Physiol. 276:F382-F389			
CB	CL	VUKICEVIC,S. et al., 1998. "Osteogenic protein-1 (Bone 30 morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat", J.Clin.Invest. 102:202-214.			
CB	CM	SURENDRAN,K., et al., 2002. "A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol", 282:F431-F441.			
CB	CN	SASSY-PRIGENT et al., 1995. "Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats", Lab Invest 73:64-71			
CB	CO	GOULD,S.E., et al., 2002 "BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells", Kidney International 61:51-60			
CB	CP	YAMAMOTO,T. et al., 1993. "Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy" Proc.Natl.Acad.Sci.U.S.A. 90:1814-1818			
CB	CQ	MORRISSEY,J., et al., 2002. "Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function" J.Am.Soc.Nephrol. 13:S14-S21.			
CB	CR	IWANO,M., et al., 2002. "Evidence that fibroblasts derive from epithelium during tissue fibrosis", J.Clin.Invest. 110:341-350			
CB	CS	HILL,C., et al., 2000. "The renal expression of transforming growth factor- β isoforms and their receptors in acute and chronic experimental diabetes in rats", Endocrinology 141:1196-1208			
CB	CT	WANG,S. et al., 2001. "Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy", J.Am.Soc.Nephrol. 12:2392-2399			
CB	CU	BRENNER et al. 1994 "Chronic Renal Failure" In Harrison's Principles of Internal Medicine, 13 th Edition, Isselbacher et al. (eds.), McGraw-Hill, Inc. New York pp. 1274-1281			
CB	CV	GLASSOCK et al 1994 "Immunopathogenic Mechanisms of Renal Injury". In Harrison's Principles of Internal Medicine, 13 th Edition, Isselbacher et al. (eds.) McGraw-Hill, Inc. New York pp. 1292-1295			
CB	CW	BOWIE et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science, (1990 March) 247(4948) 1306-10.			
CB	CX	KEES-FOLTS et al. Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome, American Journal of Nephrology (1993) 13(5):365-75			
CB	CY	COE et al. "Approach to the patient with diseases of the kidney and urinary tract", Chapter 237, Harrison's Principles of Internal Medicine, 13 th ed. Isselbacher et al (eds). New York, McGraw-Hill, p 1252, 1994			
CB	CZ	GLASSOCK, R.J. "Immunosuppressive treatment in the prevention of renal failure in primary glomerular diseases", Clinical and Experimental Dialysis and Apheresis, (1981) 5 (1-2) 21-46			

Examiner Signature	<i>Christina Berger</i>	Date Considered	9/5/06
--------------------	-------------------------	-----------------	--------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3	Attorney Docket Number	JJJ-P01-599
-------	---	----	---	------------------------	-------------

OB	CA1	CARPENTER et al., "Dialysis and transplantation in the treatment of renal failure", Chapter 238, Harrison's Principles of Internal Medicine, 13 th ed. Isselbacher et al. (eds). New York, McGraw-Hill, page 1281, 1994	
CB	CB1	TOLINS et al., "Mechanisms of hypertensive glomerular injury", American Journal of Cardiology (1988 Oct 5) 62(911) 54G-58G	
CB	CC1	PONTICELLI et al. "Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults", Clinical Nephrology (1991) 35 Suppl 1 S16-21	
CB	CD1	KLAHR et al., "The progression of renal disease", N Engl J. Med, 1988 June 23; 318(25): 1657-66	
CM	CE1	WATANABE et al., "Production of hydrogen peroxide by neutrophilic polymorphonuclear leukocytes in patients with diabetic nephropathy", Journal of Clinical Laboratory Analysis", (1993) 7 (4) 209-13	
OB	CF1	HIRSCHBERG, et al., "Effects of insulin-like growth factor I on renal function in normal men", (1993) Kidney Intl. 43:387-397	
CB	CG1	BARD et al., "Towards a genetic basis for kidney development", (1994) Mech. Development 48: 3-11	
CB	CH1	SAMPATH et al., "Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation", (1981), Proc. Natl. Acad. Sci. USA 78: 7599-7603	
CB	CI1	WANG et al. (2003) Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int.;63(6):2037-49	
CB	CJ1	YANG et al. (Aug. 1998) Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney, Nephrology, Dialysis, Transplantation ,13 (8) 1967-74	
OB	CK1	FLOEGE et al. (Apr 1992) Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model, Laboratory Investigation, 66(4)	
OB	CL1	SCHILLER et al. (March 1997) Focal glomerulosclerosis in the remnant kidney model-an inflammatory disease mediated by cytokines, Nephrology, Dialysis, Transplantation, 12(3), 430-7	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Christina Boegest</i>	Date Considered	9/5/06
--------------------	--------------------------	-----------------	--------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	10/650326
				Filing Date	August 28, 2003
				First Named Inventor	Keith A. Hruska
				Art Unit	1646
				Examiner Name	E. Kemmerer
Sheet	1	of	1	Attorney Docket Number	JJJ-P01-599

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (<i>if known</i>)	MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY		
					⁷

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>CB</i>	CM1	MOGENSEN et al., "Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and Lisinopril microalbuminuria (CALM) study", BMJ, vol. 321, pp. 1440-1444, (2000).			
<i>CB</i>	CN1	LEWINGTON et al., "Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits?", Nephrol Dial Transplant 16: Editorial Comments, pp. 885-888 (2001).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Christina Borgest</i>	Date Considered	9/6/2006
--------------------	--------------------------	-----------------	----------

9931129_1